A new study in Translational Oncology highlights the potential of inflammatory biomarkers to improve risk stratification and support personalized treatment in advanced NSCLC.
Inflammatory Biomarkers May Improve Risk Stratification in Advanced Lung Cancer
A recent study published in Translational Oncology highlights the potential of inflammatory biomarkers to improve risk assessment in patients with advanced non-small cell lung cancer (NSCLC).
The researchers found that biomarkers such as C-reactive protein (CRP) and albumin provide valuable prognostic information for patients who show stable disease at first restaging. Combined with clinical parameters, these markers may help identify patients at increased risk of early disease progression and support more personalized treatment strategies.
Danube Private University is proud to have contributed to this research through the participation of Univ.-Prof. Dr. Julia Furtner-Srajer. The study was led by the Medical University of Vienna and demonstrates the value of interdisciplinary collaboration in advancing precision oncology and improving patient care.
Reference:
